Dear Friends,

There has been a lot of activity at the ECFS since the last edition of our newsletter and here is a brief review of the special projects, what’s new with our society and a few highlights of the upcoming 41st European Cystic Fibrosis Conference taking place in a few days, this year in Belgrade, Serbia.

Changes in the ECFS Board are already happening. Isabelle Fajac as President Elect has been closely involved in the running of the Society and will officially start her 3 year mandate as ECFS President this June at the Annual General Meeting.

Let me remind you of the ECFS Board elections, which are taking place this month. There are three vacancies this year. Prof. Harm Tiddens and Prof. Daniel Peckham both finish their first terms and we wish to express our gratitude to both for their contribution to the Board over the past 3 years. And as I will be finishing my term as ECFS President, this leaves another open position for a Board member.

We have five candidates for the three positions left vacant. It is very important therefore that you as members of ECFS consider carefully and vote accordingly to your assessment of the proposed candidates. It is essential that the Board has a strong and engaged membership to provide leadership to the Society.
The results of the elections will be announced at the AGM on Friday 08 June (18:30-19:30). We very much hope that as many of you as possible will attend the AGM. We value your involvement and it is really important to have members contribute and input new ideas. More information on the AGM will appear further down in the newsletter.

In January, the ECFS Clinical Trials Network and the ECFS Patient Registry held their Steering Group meetings in Brussels, Belgium. Both the CTN and ECFS PR remain key projects of the Society. There will be a possibility for new sites to integrate the CTN network in 2019. An information session will be organised in Belgrade on Friday 08 June at 12:10-12:35 (ePoster Corner A, close to the ECFS booth in the exhibition area).

The 15th ECFS Diagnostic Network Working Group Meeting took place in St-Gallen, Switzerland in February, hosted by Jürg Barben.

The ECFS Basic Science Conference was held in Greece this year, 21-24 March 2018. Once again, the conference was a resounding success. We would like to thank the organisers, Marcus Mall (DE), Isabelle Callebaut (FR) and John Engelhardt (US) for putting together a high-quality programme. The abstract book is available on the ECFS website.

We are rapidly approaching our annual conference in Belgrade and the final preparations are well under way. The Scientific Committee has put together an outstanding programme and we have some exciting new basic research and results from clinical trials to discuss. You can find the final programme on the ECFS website. We would like to thank the Scientific Committee and the Steering Committee for all their hard work over the last year in preparing the programme, selecting the abstracts and sorting the various sessions. Besides the conference Smartphone Application featuring the programme and other useful information, other recent initiatives include the Interactive Case studies session, some ‘meet the expert’ sessions organised at lunchtime and open to all, and the ECFS Tomorrow lounge which will feature a series of interesting sessions.

As part of our commitment to support young researchers, three Young Investigators Awards and 18 travel grants have been awarded to young investigators based on the merit of their abstract submissions.

Please don’t miss a visit to the “CF Community” booth area in the Exhibition Hall for information on the various initiatives and programmes. If you are looking for a position or have a job opening to advertise, please send us the information to post on the website and bring an A4 advertisement to the ECFS booth at the conference.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in Cystic Fibrosis contained at the end of this Newsletter.

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Kris De Boeck
ECFS President
02. ECFS Board Elections - Cast your vote!

The ECFS is holding elections for 3 ECFS Board Members Positions: Harm Tiddens and Daniel Peckham have completed a first term. Invitations to take part in the elections have been sent to the ECFS electorate by email. Candidates information and links to supporting documents such as the candidates’ nominations, application letters and CVs are available on the ECFS website. Job Descriptions are available for Board members. The election deadline is 7 June 2018, 19:30 CEST.

03. ECFS Annual General Meeting @ Belgrade 2018

The Annual General Meeting will be held on Friday, 08 June 2018, 18:30-19:30, at the Sava Conference Centre in Belgrade (Annex B).

The Annual General Meeting agenda:
1. President’s Report – Kris De Boeck
2. Secretary’s Report – Harm Tiddens
3. Treasurer’s Report – Harm Tiddens
4. ECFS Board Elections – Harm Tiddens
5. Update on Journal of Cystic Fibrosis – Scott Bell
6. CTN Report – Silke van Koningsbruggen-Rietschel
7. ECFS Standards of Care Report – Pavel Drevinek
8. ECFS Patient Registry Report – Lutz Nährlich
9. ECFS Working Group Reports
   - Antimicrobial Resistance Working Group
   - Basic Science Working Group
   - Diagnostic Network Working Group
   - Exercise Working Group
   - Fungal Pathogens Working Group
   - Mental Health Working Group
   - Neonatal Screening Working Group
10. ECFS Special Interest Groups
    - Nursing Special Interest Group
    - European CF Pharmacy Group
    - European CF Nutrition Group
    - European Psychosocial Special Interest Group
11. Presentation of the 2019 European CF Conference
12. AOB

We hope to see you!
04. Belgrade Highlights

As you know, the annual ECFS conference taking place in Serbia this year. You can find all the details about the scientific programme here.

- Below are some highlights of the conference. **Looking forward to seeing you in sunny Belgrade!**
More than 65% of the delegates downloaded and used the Conference App in Seville last year. Via the app, you will be able to view all the information on the scientific programme, the exhibitors, the abstracts and ePosters. The ECFS 2018 Conference App is designed to enhance the experience of the participants before, during and after the Conference. Further information is available on the conference website and the App will be ready to download in the coming days.
06. ECFS Award 2018

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of Cystic Fibrosis or to the treatment or care of patients with Cystic Fibrosis. This year, the ECFS wishes to acknowledge Dr. Susan Madge.

Su has been a leader and pioneer in the development of multidisciplinary care for people with cystic fibrosis for over 30 years. She started her career at Great Ormond Street Hospital, caring for children with CF and moved to adult CF care at the Royal Brompton Hospital in 2002. She has lived through the transition of CF from a disease of childhood to predominantly a disease of adults. Her vision has been to ensure that the best care possible is available to people with CF of any age.

She has been a member, contributor and editor of various national and European guideline working groups, from the first UK Standards of Care in 2001 up to the recent ECFS Best Practice Guidelines, 2018. She has also been a member of various committees aiming to introduce change, from the introduction of new born screening in the UK, to recent challenges of delivering future care for adults across Europe. Her early research work centred on the family experience of cystic fibrosis exploring the emotional and behavioural problems of healthy siblings and parental quality of life. This theme has been sustained throughout her career. She is currently leading a programme using digital technology to improve care delivery in CF.

Su launched the International Nurse Specialist Group in 1998 (now the ECFS Nursing SIG) and has worked tirelessly to raise the profile of nursing and allied health professionals and their roles within the cystic fibrosis community. She has negotiated for the recognition of nursing and allied health professionals within the European CF conference, ensuring parallel sessions within the body of the conference and providing a platform for education of multidisciplinary teams. She is the only non-medical doctor/scientist to have served on the Board of the ECFS, having been elected in 2006 and re-elected in 2010 until 2014.

Education has been at the core of her work. She started the first university accredited course in managing the care of cystic fibrosis in 1996, with over 1000 multidisciplinary participants from across Europe. Internationally, her role in education has reached from Moscow and Riyadh to Sydney and Sao Paulo, often working with Cystic Fibrosis Worldwide and Cystic Fibrosis Europe. She also set up the ECFS Preceptorship Programme for training CF clinicians of the future from all disciplines.

07. Gerd Döring Award

Professor Gerd Döring was an outstanding leader of the ECFS. During his Presidency the number of members doubled. During this time he also initiated a highly successful annual conference on basic science and consensus conferences on the treatment of lung infection, early intervention and prevention of lung disease, drug inhalation and related devices, nutrition, along with recommendations for several clinical trials in Cystic Fibrosis, which have had a significant impact on treatment.

The support of young investigators was a high priority for him and to honour his enormous contribution, the ECFS has initiated a Gerd Döring Award that will be given annually to honour an exceptional early career young European scientist.

The award is primarily judged on a paper published in the previous 3 calendar years, which has made a significant impact on the understanding or treatment of Cystic Fibrosis. This year, the Gerd Döring Award has been granted to Dr. Tavs Qvist, in acknowledgement of his recent remarkable contribution to Cystic Fibrosis. The Award, which includes a monetary grant of 5,000 Euro to support research, will be presented during the Opening Plenary of the Belgrade Conference.

Tavs started as a physician at the Copenhagen CF Center in 2010, working first in the pediatric department, then in the lung transplant unit, before transitioning to adult CF care. In all three clinical settings he saw first-hand the growing problem of *Mycobacterium abscessus* complex among CF patients. His first CF
publication was on the clinical feasibility of lung transplantation in *M. abscessus* patients, which was highlighted in the recent US CF Foundation and European CF Society’s consensus recommendations for the management of nontuberculous mycobacteria. He argued that NTM disease should not be an absolute contraindication to lung transplantation, giving hope to a growing number of young CF patients, whose only hope for survival is receiving a lung transplantation. He went on to write a clinical PhD, which showed how prevalence rates were on the rise in Scandinavia, especially striking young CF patients with the most severe CF mutations. He showed that *M. abscessus* leads to death or lung transplantation within just 14 years of time of infection, making it one of the most serious threats to CF patients.

Together with Professor Niels Høiby, he went on to develop an antibody assay for diagnosing *M. abscessus*. The ELISA assay was tested in the Danish CF population demonstrating that it could be used to effectively risk-assess CF patients, selecting those in need of higher culture frequency. The method proved to be a rational approach to *M. abscessus* diagnosis, which could lead to faster and more effective disease management. A similar method for *M. avium* complex was developed and tested following this.

Tavs collaborated with Andres Floto and Charles Haworth’s research team, spending a summer in Cambridge in order to whole genome sequence the Danish *M. abscessus* isolates, confirming the worrying suspicion that human-to-human transmission can take place. This resulted in a 2016 publication in Science, which apart from increasing our understanding of this emerging threat, also identified and ended an outbreak at the Copenhagen CF Center.

Tavs went on to conduct a study of explanted CF lungs, where he was the first to show that *M. abscessus* is a biofilm infection in the CF lung, a finding, which has implications for how to manage and treat *M. abscessus* infection. His newest research plans are directed at early eradication of *M. abscessus* and the identification of novel biofilm targets.

---

**08. CF Courses**

Education is one of the major objectives for the ECFS. Several courses will be organised prior to the conference:

- CF Course – the Treatment of Adults with CF – an in-Depth Course
- An Introductory Course in Cognitive Behavioral Therapy and Interpersonal Therapy
- Nutrition Masterclass - Practical management of nutrition issues in CF
- Physiotherapy Short Course - Airway clearance techniques: basic approach

More information about these courses can be found [here](#)
09. ECFS Tomorrow

We see the ECFS Tomorrow as a means to improve one of the fundamental objectives of the Society – to support and engage young scientists working in the field of Cystic Fibrosis. It is essential to provide professionals who are new to the community with opportunities to connect in a meaningful way with current leaders and experts. In turn, the new generation of specialists bring up-to-date approaches and practices to the wealth of experience that already exists within the society’s ranks.

Located in the Exhibition Area of the conference venue, the ECFS Tomorrow Lounge will feature interactive workshops and a debate on Thursday and Friday. Come and take an active part in the debate and discussions on different aspects of cystic fibrosis management and care.

<table>
<thead>
<tr>
<th>WEDNESDAY, JUNE 6</th>
<th>FRIDAY, JUNE 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>20:00 – 21:00</td>
<td>Meet &amp; Greet</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>THURSDAY, JUNE 7</td>
<td>FRIDAY, JUNE 8</td>
</tr>
</tbody>
</table>
| 12:45 – 13:45     | 12:45 – 13:45 | Body Composition – Practical considerations and techniques
| Mental health Guidelines from East to West (and back). Local adaptation of the implementation of the MH guidelines | Elizabeth Owen, London, UK |
| Pavla Hodkova, Prague, CZ / Diana Kadosh, Petah Tikva, IL / Urszula Borawska- Kowalczyk, Warsaw, PL / Anna Georgiopoulos, Boston, US |
| Managing challenging behaviour in young people with CF during in-patient stays* | 15:15 – 16:15 |
| Kath MacDonald, Edinburgh, UK / Ann Raman, Ghent, BE |
| 14:00 – 15:00     | MyCyFAPP: holistic system for children’s nutrition and PERT self-management |
|                   | SATURDAY, JUNE 9 |
| 10:30 – 11:00     | Farewell coffee |
|                   |               |
## Meetings and Courses in Belgrade

<table>
<thead>
<tr>
<th>Tuesday 5 June 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 17:00</td>
</tr>
<tr>
<td>08:30 17:30</td>
</tr>
<tr>
<td>13:30 17:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wednesday 6 June 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 17:00</td>
</tr>
<tr>
<td>09:00 17:00</td>
</tr>
<tr>
<td>10:00 16:40</td>
</tr>
<tr>
<td>10:00 12:00</td>
</tr>
<tr>
<td>17:00 18:00</td>
</tr>
<tr>
<td>08:30 15:30</td>
</tr>
<tr>
<td>13:15 17:00</td>
</tr>
<tr>
<td>09:00 14:00</td>
</tr>
<tr>
<td>16:00 18:00</td>
</tr>
<tr>
<td>09:30 15:00</td>
</tr>
<tr>
<td>09:00 16:20</td>
</tr>
<tr>
<td>12:30 13:30</td>
</tr>
<tr>
<td>13:30 16:00</td>
</tr>
<tr>
<td>16:30 18:00</td>
</tr>
<tr>
<td>09:00 16:30</td>
</tr>
<tr>
<td>14:00 18:00</td>
</tr>
<tr>
<td>09:30 16:45</td>
</tr>
<tr>
<td>12:30 14:00</td>
</tr>
<tr>
<td>17:00 18:30</td>
</tr>
<tr>
<td>08:30 12:15</td>
</tr>
<tr>
<td>14:30 17:00</td>
</tr>
<tr>
<td>17:00 18:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Thursday 7 June 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 14:00</td>
</tr>
<tr>
<td>12:30 14:30</td>
</tr>
<tr>
<td>Time</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>18:30</td>
</tr>
<tr>
<td>18:30</td>
</tr>
<tr>
<td>10:00</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>13:30</td>
</tr>
<tr>
<td>18:00</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>19:00</td>
</tr>
<tr>
<td>07:00</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>15:00</td>
</tr>
<tr>
<td>18:30</td>
</tr>
<tr>
<td>12:30</td>
</tr>
<tr>
<td>13:30</td>
</tr>
</tbody>
</table>

* By invitation only
** Extra registration needed
11. Conect4children (c4c)

Better medicines for babies, children and young people through a pan-European clinical trial network. Conect4children is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population. The ECFS-CTN will participate in the work package on training and education. The press release is available here.

12. 2018 ECFS Basic Science Conference - Loutraki, Greece

The ECFS Basic Science Conference was held in Loutraki, Greece between 21 and 24 March 2018. With more than 200 participants, the conference was a resounding success. We would like to thank the organisers, Marcus Mall (DE), Isabelle Callebaut (FR) and John Engelhardt (US) for putting together a high quality programme. The abstract book is available on the ECFS website.

Isabelle Callebaut (FR), Carlos Farinha (PT) and Martin Mense (US) will be the organisers of the 2019 edition of the ECFS Basic Science Conference.

13. ECFS Basic Science WG Workshop

The Basic Science Working Group will organise the 3rd “Hands-on Workshop Epithelial Systems: Physiology and Pathophysiology”. It will take place in Lisbon, 23 – 27 July 2018. Free registration - Some travel grants are available. To apply, please send a CV, letter of motivation and recommendation letter to ESP2018@fc.ul.pt. Deadline for application: 10 June 2018. Read more
14. ECFS DNWG Workshop

ECFS Diagnostic Network Working Group Sweat test Training Workshop

Practical aspects for improvement of CF diagnosis in Europe - Call for applications

From an ECFS Diagnostic Network Working Group (DNWG) survey we have learned about important deficiencies in sweat test routine in real life in Europe (Cirilli N et al. JCF 2017).

Therefore, as a next step the DNWG is organising a hands-on workshop for sweat test procedure according to international guidelines and the ECFS CTN sweat test SOP.

It will take place in Belgrade, Serbia on Wednesday 6 June 2018, 15:00-17:00.

Workshop topics:
- Introduction by workshop staff about most relevant details/most common errors (15min)
- setup of 5 sweat test stations (3-4 people each, each station will be supervised by a DNWG group member)
- 1 Chloridemeter/Chlorocheck for practical realtime sweat analysis onsite
- Practical training: stimulation, collection, analysis (90 min)
- Q&A (15min)

Applications are welcome from all ECFS members. The workshop will be free of charge and will be limited to a group of max. 20 participants.

Please send your application informally via mailto: dnwg@ecfs.eu

Deadline for application: 31 May 2018

15. Job Posting

Brussels (BE) - The laboratory of Teresinha LEAL is offering a postdoc position in the field of Cystic Fibrosis at the Louvain centre for Toxicology and Applied Pharmacology, one research centre of the Institut de Recherche Expérimentale et Clinique (IREC) situated on the campus of the Université catholique de Louvain, one of the leading higher educational organisations in Brussels, Belgium.

Read more

PhD position in Newcastle (UK) - The Institutes for Cell & Molecular Biosciences & Cellular Medicine are offering a PhD position. Project: Personalised Therapies for all: Restoring airway function in CF using Alternative Chloride Channels (ACCs). Deadline for applications: 18 July 2018

Contact person: Dr Mike Gray - m.a.gray@newcastle.ac.uk

Read more

PhD position in Regensburg (DE) - The University of Regensburg, Department of Physiology, is offering a PhD position. Project: Investigation of drugs that modulate ion transport and mucus secretion as a novel treatment of cystic fibrosis

Contact person: Prof. Karl Kunzelmann - karl.kunzelmann@ur.de

Read more

Postdoctoral position in Paris (FR) - The team of the Centre de Recherche des Cordeliers (CRC) -Institut Necker Enfants Malades (INEM) is offering a Post Doc position in the field of Cystic Fibrosis.

Project: Atp12a as a novel therapeutic target in cystic fibrosis lung disease.

Contact: I. Sermet-Gaudelus - isabelle.sermet@aphp.fr G.Crambert - gilles.crambert@crc.jussieu.fr

Read more
15. Upcoming Events
- ECFS Board Meeting 05 June 2018, Belgrade, Serbia
- ECFS Annual General Assembly - 08 June 2017 – Belgrade, Serbia
- 41st European CF Conference - 06-09 June 2018 – Belgrade, Serbia
- 2018 European Respiratory Society Congress 15-19 September 2018 – Paris, France
- North American CF Conference, 18-20 October 2018, Denver, CO, United States
- 42nd European CF Conference – 05-08 June 2019, Liverpool, United Kingdom

16. Current References in Cystic Fibrosis
Please go to next page.
Pancreatic and Islet Remodeling in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Knockout Ferrets
American Journal of Pathology 2018; 188: 876 - 890

Evaluation of autophagy inducers in epithelial cells carrying the Delta F508 mutation of the cystic fibrosis transmembrane conductance regulator CFTR
Cell Death & Disease 2018; 9: ArNo: 191

Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer
Cellular and Molecular Life Sciences 2018; 75: 1737 - 1756

Clinical
ECFS best practice guidelines: the 2018 revision
Journal of Cystic Fibrosis 2018; 17: 153 - 178

Duncan JA., Brown SMN.
The impact of co-morbidity in childhood cystic fibrosis
Paediatric Respiratory Reviews 2018; 26: 13 - 15

Espel JC., Palan HL., Bharat A., Cullina J., Prickett M., Sala M., McColey SA., Jain M.
The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype
Journal of Cystic Fibrosis 2018; 17: 34 - 42

Friedman D., Linnemann RW., Altstein LL., Islam S., Bach KT., Lamb C., Volpe J., Doolittle C., John AS., O’Malley PJ., Sawicki GS., Giagopoulous AM., Yonker LM., Moskowitz SM.
The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping
Journal of Cystic Fibrosis 2018; 17: 71 - 77

Garinis AC., Keefe DH., Hunter LL., Fitzpatrick DF., Putterman DB., McMillan GP., Gold JA., Feeney MP.
Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Otoxicity in Cystic Fibrosis Patients
Ear and Hearing 2018; 39: 69 - 84

Harutyunyan M., Huang YJ., Mun KS., Yang FMY., Arora K., Naren AP.
Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations
American Journal of Physiology-Lung Cellular and Molecular Physiology 2018; 314: 1529 - 1543

Langeard C., Minguet G.
Genealogy of good practices of hygiene: Local declensions and work of agreement in the case of cystic fibrosis
Sciences Sociales Et Sante 2018; 36: 71 - 97

Paranjape SM., Mogayzel PJ.
Cystic fibrosis in the era of precision medicine
Paediatric Respiratory Reviews 2018; 25: 64 - 72

Rivas-Cilleros E., Lopez-Alonso JC.
Nurse contribution in the treatment of cystic fibrosis
Enfermeria Clinica 2018; 28: 75 - 76

Databases & Registries
[Anonymous].
Italian Cystic Fibrosis Registry Center Dot Report 2011-2014
Epidemiologia & Prevenzione 2018; 42:

Keogh RH., Stanoevich S.
A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports
Journal of Cystic Fibrosis 2018; 17: 213 - 217

Keogh RH., Szczesniak R., Taylor-Robinson D., Bilton D.
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data
Journal of Cystic Fibrosis 2018; 17: 218 - 227
Diabetes

Ballmann M., Holl RW.
Treatment of cystic fibrosis-related diabetes reply
*Lancet Diabetes & Endocrinology* 2018; 6: 167 - 168

Ballmann M., Hubert D., Assael BM., Staab D., Hebestreit A., Naehrlich L., Nickolay T., Prinz N., Holl RW.
Regapilamide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial
*Lancet Diabetes & Endocrinology* 2018; 6: 114 - 121

Hart NJ., Aramandla R., Poffenberger G., Fayolle C., Thames AH., Bautista A., Spiegelman AF., Babon JAB., DeNicola ME., Dadi PK., Bush WS., Balamurugan AN., Braggion C., Cirilli N., Braggion C., Mergni G., Polizzi AM., Padoan R., Dunitz JM., Dunn T., Pruett TL., Sutherland DER., Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis
*Journal of Endocrinological Investigation* 2018; 41: 591 - 596

Preville-Ratelle S., Coriati A., Menard A., Bourdeau L., Tremblay F., Berthiaume Y.
Adrenal Insufficiency in Cystic Fibrosis: A Rare Phenomenon?
*Canadian Respiratory Journal* 2018; ArNo: 3629031

Exercise

Foster K., Huang GX., Zhang NH., Crisalli J., Chini B., Amin R., Elder D.
Relationship between exercise capacity and glucose tolerance in cystic fibrosis
*Pediatric Pulmonology* 2018; 53: 154 - 161

Hebestreit H., Lands L.C., Alarie N., Schaeff J., Karila C., Orenstein DM., Uruquhart DS., Hulzebos EJH., Stein L., Schindler C., Kriemler S., Radtke T.
effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol
*BMC Pulmonary Medicine* 2018; 18: ArNo: 31

Lim CA., de Andrade AD., Campos SL., Brandao DC., Mourato IP., de Britto MCA.
Six-minute walk test as a determinant of the functional capacity of children and adolescents with cystic fibrosis: a systematic review
*Respiratory Medicine* 2018; 137: 83 - 88

Mackintosh KA., Ridgers ND., Evans RE., McNarry MA.
Physical Activity and Sedentary Time Patterns in Children and Adolescents With Cystic Fibrosis and Age- and Sex-Matched Healthy Controls
*Journal of Physical Activity & Health* 2018; 15: 82 - 88

Relationship between Physical Activity and Fatigue in Adults with Cystic Fibrosis
*Physiotherapy Canada* 2018; 70: 42 - 49

Tucker MA., Berry B., Seigler N., Davison GW., Quindry JC., Eldson D., McKie KT., Harris RA.
Blood flow regulation and oxidative stress during submaximal cycling exercise in patients with cystic fibrosis
*Journal of Cystic Fibrosis* 2018; 17: 256 - 263

Gastroenterology

Benezech A., Desmaze-Dufou E., Baunstaerk C., Bouvier M., Colley B., Reynaud-Gaubert M., Vition V.
Prevalence of Fecal Incontinence in Adults with Cystic Fibrosis
*Digestive Diseases and Sciences* 2018; 63: 982 - 988

Colling KP., Bellin MD., Schwarzenberg SJ., Berry L., Wilhelm JJ., Dunn T., Pruett TL., Sutherland DER., Chinnakota S., Dunitz JM., Beilman GJ.
Total Pancreatectomy With Intraportal Islet Autotransplantation as a Treatment of Chronic Pancreatitis in Patients With CFTR Mutations
*Pancreas* 2018; 47: 238 - 244

Engjom T., Tjora E., Wathle G., Erchinger F., Laerum BN., Gilja OH., Haldorsen IS., Dimecvski G.
Secretin-stimulated ultrasound estimation of pancreatic secretion in cystic fibrosis validated by magnetic resonance imaging
*European Radiology* 2018; 28: 1495 - 1503
Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10 years old
Journal of Cystic Fibrosis 2018; 17: 109 - 113

Gelfond D., Heltsle SL., Skalland M., Heubi JE., Kloster M., Leung DH., Ramsey BW., Borowitz D.
Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening
Journal of Pediatric Gastroenterology and Nutrition 2018; 66: 567 - 563

Krylova NA., Amelina EL., Krasovsky SA., Karchevskaya NA., Tarabrin EA., Gasanov AM., Ihragimova DF., Golovinsky SV.
Enteral tube feeding in adult patients with cystic fibrosis and respiratory failure
Terapevticheskii Arkhiv 2017; 89: 51 - 55

Linkson L., Macedo P., Perrin FMR., Elston CM.
Anorexia nervosa in cystic fibrosis
Paediatric Respiratory Reviews 2018; 26: 10 - 24

Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis Mediators of Inflammation 2018; : ArNo: 1601486
Waldhausen JHT., Richards M.
Meconium ileus
Clinics in Colon and Rectal Surgery 2018; 31: 121 - 126

Gene Therapy

Fernandez EF., Santos-Carbajal B., de Santci C., Ramsey JM., MacLoughlin R., Cryan SA., Greene CM.
Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies
Materials 2018; 11: 1:122

Gruntman AM., Flotte TR.
The rapidly evolving state of gene therapy
FASEB Journal 2018; 32: 1733 - 1740

Harrison PT., Hoppe N., Martin U.
Gene editing & stem cells
Journal of Cystic Fibrosis 2018; 17: 10 - 16

Mottais A., Berchel M., Sibirl Y., Laurent V., Gill D., Hyde S., Jaffres PA., Monier T., Le Gall T.
Antibacterial effect and DNA delivery using a combination of an arsonium-containing lipophosphoramide with an N-heterocyclic carbene-silver complex - Potential benefits for cystic fibrosis lung gene therapy
International Journal of Pharmaceutics 2018; 536: 29 - 41

Ren CL., Morgan RL., Oermann C., Resnick HE., Brady C., Campbell A., DeNagel R., Guilt M., Hoag J., Lipton A., Newton T., Peters S., Willey-Courand DB., Naureckas ET.
Cystic Fibrosis Foundation Pulmonary Guidelines Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis

General Review

Doull I.
Cystic Fibrosis Papers of the Year 2016
Paediatric Respiratory Reviews 2018; 26: 10 - 12

Rubin BK.
Cystic Fibrosis 2017-The Year in Review
Respiratory Care 2018; 63: 238 - 241

Shawcross A., Barry PJ.
Highlights from the 30th North American Cystic Fibrosis Conference, Orlando 2016
Paediatric Respiratory Reviews 2018; 26: 1 - 3

Genetics

Blue E., Louie TL., Chong JX., Hebrbing SJ., Barnes KC., Rafael NM., Knowles MR., Gibson RL., Bamshad MJ., Emond MJ.
Variation in Cilia Protein Genes and Progression of Lung Disease in Cystic Fibrosis

FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition
Journal of Cystic Fibrosis 2018; 17: 190 - 203

The CFTR gene mild variants poly-T, TG repeats and M470V detection in Indian men with congenital bilateral absence of vas deferens
Andrologia 2018; 50: 2:e12858

Targeted sequencing reveals complex, phenotype-correlated genotypes in cystic fibrosis
BMC Medical Genomics 2018; 11:

Marson FAL.
Disease-modifying factors in cystic fibrosis
Current Opinion in Pulmonary Medicine 2018; 24: 296 - 308

Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics
Clinical Respiratory Journal 2018; 12: 1197 - 1206

Growth & Development

Gibson HT., McDonald CM., Derrick JW., Eggert DL., Bellini SG.
Evaluating Changes in Handgrip Strength in Children With Cystic Fibrosis: A Pilot Study
Nutrition in Clinical Practice 2018; : ArNo: 1601486

Mathiesen H., Pressler T., Oturai P., Katzenstein TL., Skov M., Frikke-Schmidt R., Hitz MF.
Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis
International Journal of Endocrinology 2018; : ArNo: 4803974

Nishiyama KK., Agarwal S., Kepley A., Rosette F., Hu YZ., Guo XE., Keating CL., DiMango EA., Shane E.
Adults with cystic fibrosis have deficits in bone structure and strength at the distal tibia despite similar size and measuring standard and relative sites
Bone 2018; 107: 181 - 187

Stahl M., Holfelder C., Kneppp C., Kieser M., Kasperk C., Schoenau E., Sommerburg O., Tonshoff B.
Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 114 - 120

Eggett DL., Bellini CM.
Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics
Clinical Respiratory Journal 2018; 12: 1197 - 1206

Hodges CA., Boelle PY., Guillot L.
The CFTR gene mild variants poly-T, TG repeats and M470V detection in Indian men with congenital bilateral absence of vas deferens
Andrologia 2018; 50: 2:e12858

Targeted sequencing reveals complex, phenotype-correlated genotypes in cystic fibrosis
BMC Medical Genomics 2018; 11:

Marson FAL.
Disease-modifying factors in cystic fibrosis
Current Opinion in Pulmonary Medicine 2018; 24: 296 - 308

Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics
Clinical Respiratory Journal 2018; 12: 1197 - 1206

Growth & Development

Gibson HT., McDonald CM., Derrick JW., Eggert DL., Bellini SG.
Evaluating Changes in Handgrip Strength in Children With Cystic Fibrosis: A Pilot Study
Nutrition in Clinical Practice 2018; : ArNo: 1601486

Mathiesen H., Pressler T., Oturai P., Katzenstein TL., Skov M., Frikke-Schmidt R., Hitz MF.
Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis
International Journal of Endocrinology 2018; : ArNo: 4803974

Nishiyama KK., Agarwal S., Kepley A., Rosette F., Hu YZ., Guo XE., Keating CL., DiMango EA., Shane E.
Adults with cystic fibrosis have deficits in bone structure and strength at the distal tibia despite similar size and measuring standard and relative sites
Bone 2018; 107: 181 - 187

Stahl M., Holfelder C., Kneppp C., Kieser M., Kasperk C., Schoenau E., Sommerburg O., Tonshoff B.
Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 114 - 120
Immunology & Inflammation

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis
Thorax 2018; 73: 134 - 144

Hull RL., Gibson RL., McNamara S., Deutsch GH., Fligner CL., Frevert CW., Ramsey BW., Sanda S.
Islet Interleukin-1 beta Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to beta-Cell Failure
Diabetes Care 2018; 41(12): 2482 - 830

Jat KR., Walia DK., Khairwa A.
Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2018; : CD010288

Lower exhaled nitric oxide in infants with Cystic Fibrosis compared to healthy controls
Journal of Cystic Fibrosis 2018; 17: 105 - 108

Leverque M., Penna A., Le Trionnaire S., Belleguic C., Desrues B., Brinchault G., Jouenne T., Lagadic-Gossman D., Martin-Choully C.
Phagocytosis depends on TRPV2-mediated calcium influx and requires TRPV2 in lipids rafts: alteration in macrophages from patients with cystic fibrosis
Scientific Reports 2018; 8: ArNo: 4310

Lindberg U., Svensson L., Hellmark T., Segelmark M., Shannon O.
Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status
Thrombosis Research 2018; 162: 32 - 37

Mauch RM., Jensen PO., Moser C., Levy CE., Hoiby N.
Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 143 - 152

McKieran PJ., Molloy KP., Cryan SA., McElvaney NG., Greene CM.
X Chromosome-encoded MicroRNAs Are Functionally Increased in Cystic Fibrosis Monocytes
American Journal of Respiratory and Critical Care Medicine 2018; 197: 668 - 670

Nadesalingam A., Chen JHK., Farahvash A., Khan MA.
Hypertonic Saline Suppresses NADPH Oxidase-Dependent Neutrophil Extracellular Trap Formation and Promotes Apoptosis
Frontiers in Immunology 2018; 9: ArNo: 359

Sheikh Z., Ong HX., Pozzoli M., Young PM., Traini D.
Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
Expert Opinion On Orphan Drugs 2018; 6: 69 - 84

Spicuzza L., Parisi GF., Tardino L., Ciancio N., Nenna R., Midulla F., Leonardi S.
Exhaled markers of antioxidant activity and oxidative stress in stable cystic fibrosis patients with moderate lung disease

Liver Disease

Ayoub F., Trillo-Alvarez C., Morell G., Lascano J.
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
World Journal of Hepatology 2018; 10: 34 - 40

Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography
Journal of Pediatric Gastroenterology and Nutrition 2018; 66: 455 - 460

Hillaire S., Cazals-Hatem D., Erlinger S., Paradis V.
Cystic fibrosis liver disease in adults: Limits of non-invasive tests of fibrosis
Hepatology 2018; 67: 798 - 799

Kamal N., Surana P., Koh C.
Liver disease in patients with cystic fibrosis
Current Opinion in Gastroenterology 2018; 34: 146 - 151

Koh C., Sakiani S., Heller T.
Cystic Fibrosis Liver Disease in Adults: Limits of Non-invasive Tests of Fibrosis Reply
Hepatology 2018; 67: 799 - 800

Ye W., Narkewicz MR., Leung DH., Karsakul W., Murray KF., Alonso EM., Magee JC., Schwarzenberg SJ., Weymann A., Molleston JP.
Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis
Journal of Pediatric Gastroenterology and Nutrition 2018; 66: 122 - 127

Microbiology

Abela IA., Murer C., Schuurmans MM., Schmitt JW., Muller F., Imkamp F., Mueller NJ., Benden C.
A cluster of scedosporiosis in lung transplant candidates and recipients: The Zurich experience and review of the literature
Transplant Infectious Disease 2018; 20: 1:e12792

Adelman MH., Addrizzo-Harris DJ.
Management of nontuberculous mycobacterial pulmonary disease
Current Opinion in Pulmonary Medicine 2018; 24: 212 - 219

Aldrovandi M., Bantihiya S., Meckelmann S., Zhou Y., Heydeck D., O'Donnell VB., Kuhn H.
Specific oxygenation of plasma membrane phospholipids by Pseudomonas aeruginosa lipoxynagen induces structural and functional alterations in mammalian cells
Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 2018; 1863: 152 - 164

Anand R., Moss RB., Sass G., Banaei N., Clemens KV., Martinez M., Stevens DA.
Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm
Mycopathologia 2018; 183: 263 - 272

Belmadi N., Wu YZ., Touqui L.
Immu-no-modulatory functions of the type-3 secretion system and impacts on the pulmonary host defense: A role for ExoS of Pseudomonas aeruginosa in cystic fibrosis
Toxicon 2018; 143: 68 - 73

Berdah L., Taytard J., Leyronnas S., Clement A., Boelle PY., Corvol H.
Stenotrophomonas maltophilia: A marker of lung disease severity
Pediatric Pulmonology 2018; 53: 426 - 430

Bodilis J., Denet E., Brothier E., Graindorge A., Favre B., Berdah L., Taytard J., Leyronnas S., Clement A., Boelle PY., Corvol H.
Fungal and Bacterial Diversity of Airway Microbiota in Adults with Cystic Fibrosis: Concordance Between Conventional Methods and Ultra- Deep Sequencing, and Their Practical use in the Clinical Laboratory
Mycopathologia 2018; 183: 171 - 183

Nutrition

Collins S. Nutritional management of cystic fibrosis - an update for the 21st century Paediatric Respiratory Reviews 2018; 26: 4 - 6

Giguere-Rich C, Mathew A, Reid E, Autore K, Guill MF. Use of an In-line Digestive Cartridge With Enteral Nutrition Improves the Weight Trajectory of 2 Children With Cystic Fibrosis Complicated by Another Medical Diagnosis Nutrition in Clinical Practice 2018; 33: 286 - 294


Revert K, Audran L, Pengam J, Lesne P, Bertrand DP. A quality improvement program to improve nutritional status of children with Cystic Fibrosis aged 2-12 years old over a 3 year period at CF Center Roscoff, Brittany Orphanet Journal of Rare Diseases 2018; 13:

Physiotherapy

Freitas DA, Chaves GSS, Santino TA, Ribeiro CTD, Dias FAL, Guerra RO, Mendonca KMPP. Standard (head-down tilt) versus modified (without head-down tilt) postural drainage in infants and young children with cystic fibrosis Cochrane Database of Systematic Reviews 2018; 3:CD010297

Gaynor M, Wood J. Mechanical insufflation-exsufflation for airway clearance in adults with cystic fibrosis Respiriology Case Reports 2018; 6: 4:UNSP e00307

Giguere-Rich C, Mathew A, Reid E, Autore K, Guill MF. Use of an In-line Digestive Cartridge With Enteral Nutrition Improves the Weight Trajectory of 2 Children With Cystic Fibrosis Complicated by Another Medical Diagnosis Nutrition in Clinical Practice 2018; 33: 286 - 294

Psychosocial

Bertrand DP., Minguet G., Gagnayre R., Lombrail P. Lessons from patient and parent involvement (P&P) in a quality improvement program in cystic fibrosis care in France Orphanet Journal of Rare Diseases 2018; 13: 168


Bertrand DP., Nowak E., Dehillion C., Lemmonier L., Rault G. Quality of care in cystic fibrosis: assessment protocol of the French QIP PHARE-M Orphanet Journal of Rare Diseases 2018; 13:


Castellanos MEP., de Barros NF., Coelho SS. Biographical ruptures and flows in the family experience and trajectory of children with cystic fibrosis Ciencia & Saude Coletiva 2018; 23: 357 - 367


del Corral T., Iranzo MACI., Lopez-de-Uralde-Villanueva L., Martinez-Alejos R., Blanco I., Villaro J. Effectiveness of a Home-Based Active Video Game Programme in Young Cystic Fibrosis Patients Respiration 2018; 95: 87 - 97


Farber JG., Prieur MG., Roach C., Shay R., Walter M., Borowitz D., Dollen EP. Difficult conversations: Discussing prognosis with children with cystic fibrosis Pediatric Pulmonology 2018; 53: 592 - 598


Garcia G., Snell C., Sawicki G., Simons LE. Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis Psychosomatics 2018; 59: 158 - 168


Gerardin M., Pede A., Poumegne-Bertrand D., Leger P., Vallet C., Bilhoeu T., David V. A quality improvement program for adolescents with cystic fibrosis: focus on psychosocial skills Orphanet Journal of Rare Diseases 2018; 13:

Hurst-Kennedy J. Cystic Fibrosis as a Theme to Incorporate Team-Based Learning in Cell Biology Courses American Biology Teacher 2018; 80: 2 - 5

Iorga M., Muraru D., Drochioi AS., Petrariu FD., Anton-Paduraru DT. Socio-demographic characteristics and reported psycho-medical symptoms for children with rare diseases. A comparative study between patients with phenylketonuria, cystic fibrosis and hypothyroidism Medical-Surgical Journal-Revista Medico-Chirurgica 2017; 121: 510 - 518


Jimenez EB., Tito VV., Cevallos WP., Rosero C., Tobar RCC., Posligua JP., Alava CXV. Anxiety and Depression in Patients with Cystic Fibrosis Treated at Eugenio Espejo Hospital in the City of Quito Acta Psiquiatrica Y Psicologica de America Latina 2017; 63: 183 - 188


Kazmerski TM., Sawicki GS., Miller E., Jones KA., Abebe KZ., Tuchman LK., Ladores S., Rubenstein RC., Saged SD., Weiner DJ., Pilewski JM., Orenstein DM., Borrero S. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis Journal of Cystic Fibrosis 2018; 17: 57 - 63

Kazmerski TM., Sawicki GS., Miller E., Jones KA., Abebe KZ., Tuchman LK., Ladores S., Rubenstein RC., Saged SD., Weiner DJ., Pilewski JM., Orenstein DM., Borrero S. Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis Journal of Cystic Fibrosis 2018; 17: 64 - 70

Ketchell RI. Telemedicine is the way forward for the management of cystic fibrosis - the case in favour Paeidiatric Respiratory Reviews 2018; 26: 19 - 21

Lenney W. Telemedicine is the way forward for the management of cystic fibrosis- the case against Paeidiatric Respiratory Reviews 2018; 26: 22 - 23


Rowbotham NJ., Smith S., Leighton PA., Rayner OC., Gathercole K., Elliott ZC., Nash EF., Daniels T., Duff AJA., Collins S., Chandran S., People U., Hurley MN., Brownlee K., Smyth AR. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers Thorax 2018; 73: 388 - 390


Pulmonology

Dittrich AS., Kuhbandner I., Gehrig S., Rickert-Zacharias V., Twigg M., Wege S., Taggart CC., Herth F., Schultz C., Mall MA. 
Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis 
*European Respiratory Journal* 2018; 51: 3:1701910

Fuger M., Aupiais C., Thounygin G., Taylard J., Tamalet A., Escudier E., Boizeau P., Corvol H., Beydon N. 
Gas exchanges in children with cystic fibrosis or primary ciliary dyskinesia: A retrospective study 
*Respiratory Physiology & Neurobiology* 2018; 251: 1 - 7

Green K., Kongstad T., Skov M., Buchvald F., Rosthoj S., Marott JL., Gustafsson P., Pressler T., Nielsen KG. 
Variability of monthly nitrogen multiple-breath washout during one year in children with cystic fibrosis 
*Journal of Cystic Fibrosis* 2018; 17: 242 - 248

Lucas SK., Yang R., Dunitz JM., Boyer HC., Hunter RC. 
16S rRNA gene sequencing reveals site-specific signatures of the upper and lower airways of cystic fibrosis patients 
*Journal of Cystic Fibrosis* 2018; 17: 204 - 212

Kim SO., Corey M., Stephenson AL., Strug LJ. 
Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries 
*Thorax* 2018; 73: 446 - 450

Khalfoun S., Tumin D., Ghossein M., Lind M., Hayes D., Kirkby S. 
Improved Lung Function after Sinus Surgery in Cystic Fibrosis Patients with Moderate Obstruction 
*Otolaryngology-head and Neck Surgery* 2018; 158: 381 - 385

Krivchenia K., Tumin D., Nemastil CJ., Tobias JD., Hayes D. 
Timing of Spirometry May Impact Hospital Length of Stay for Cystic Fibrosis Pulmonary Exacerbation 
*Lang* 2018; 196: 207 - 211

Nelson J., Karempelis P., Dunitz J., Hunter R., Boyer H. 
Pulmonary aspiration of sinus secretions in patients with cystic fibrosis 
*International Forum of Allergy & Rhinology* 2018; 8: 385 - 388

Ongarato R., da Rosa KM., Eloi JC., Epifanio M., Marostica P., Pinto LA. 
Association between hypovitaminosis D and frequency of pulmonary exacerbations in children and adolescents with cystic fibrosis 
*Einstein-SGO Paulo* 2018; 16: 1:UNSP eA04143

Rayment JH., Stanojevic S., Davis SD., Retsch-Bogart G., Ratjen F. 
Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis 
*Thorax* 2018; 73: 451 - 458

Saygi EK., Coskun OK. 
Pulmonary rehabilitation in patients with cystic fibrosis 
*Turkiye Fiziksel Tıp Ve Rehabilitasyon Dergisi-turkish Journal of 2017; 63: 96 - 103

Schechter MS., VanDevanter DR., Pasta DJ., Short SA., Morgan WJ., Konstan MW. 
Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations 

Schmid-Mohler G., Caress AL., Spirig R., Benden C., Yorke J. 
Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation 
*Respiratory Care* 2018; 63: 353 - 366

Shakkoitai A., Kaciroli N., Kasmiakha L., Nasr SZ. 
Impact of home spirometry on medication adherence among adolescents with cystic fibrosis 
*Pediatric Pulmonology* 2018; 53: 431 - 436

Use of extracorporeal membrane oxygenation in cystic fibrosis in an Australian cystic fibrosis centre 
*Internal Medicine Journal* 2018; 48: 340 - 342

Stolarczyk M., Veit G., Schnur A., Veltman M., Lukacs GL., Scholte BJ. 
Extracellular oxidation in cystic fibrosis airway epithelium causes enhanced EGFR/ADAM17 activity 

Svedberg M., Gustafsson PM., Robinson PD., Rosberg M., Lindblad A. 
Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children 
*Journal of Cystic Fibrosis* 2018; 17: 236 - 241

Ventura JC., Hauschild DB., Moreira EAM., Pereira LCR., Rosa AF., Barbosa E., Ludwig-Neto N., da Rosa JS., Frode TS., Moreno YMF. 
C-reactive protein/albumin ratio is associated with lung function among children/adolescents with cystic fibrosis: a three-year longitudinal study 
*Sao Paulo Medical Journal* 2018; 136: 29 - 36

**Radiology**

A novel approach based on low-field NMR for the detection of the pathological components of sputum in cystic fibrosis patients 
*Magnetic Resonance in Medicine* 2018; 79: 2323 - 2331

Amazoupolou C., Gnammt R., Higashigaito K., Jung A., Kellenberger CJ. 
Structural and perfusion magnetic resonance imaging of the lung in cystic fibrosis 
*Pediatric Radiology* 2018; 48: 165 - 175

Gur M., Spinelli E., Tridello G., Baltieri S., Pinalli L., Montemezzii S., Bentur L., Assael BM. 
Chest computed tomography scores in patients with cystic fibrosis colonized with methicillin-resistant Staphylococcus aureus 
*Clinical Respiratory Journal* 2018; 12: 779 - 785

Lacerda LS., Lopes AJ., Carvalho ARS., Guimaraes ARM., Firmida MC., Castro MCS., Mogami R., Melo PL. 
The Role of Multidetector Computed Tomography and the Forced Oscillation Technique in Assessing Lung Damage in Adults With Cystic Fibrosis 
*Respiratory Care* 2018; 63: 430 - 440

Non-contrast enhanced magnetic resonance imaging detects mosaic signal intensity in early cystic fibrosis lung disease 
*European Journal of Radiology* 2018; 101: 178 - 183

Kanhere N., Couch MJ., Rayment JH., Ratjen F., Santyr G. 
The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis Reply 
*American Journal of Respiratory and Critical Care Medicine* 2018; 197: 411 - 412

Konietzke P., Weinheimer O., Wielputz MO., Savages D., Ziyeh T., Tu C., Newmann B., Galban CJ., Mall MA., Kauczor HU., Robinson TE. 
Validation of automated lobe segmentation on paired inspiratory-expiratory chest CT in 8-14 year-old children with cystic fibrosis 
*PLoS One* 2018; 13: e0194557

Lam DL., Kapnадak SG., Godwin JD., Kicska GA., Aitken ML., Pipavath SN. 
Radiologic computed tomography features of Mycobacterium abscessus in cystic fibrosis 
*Clinical Respiratory Journal* 2018; 12: 459 - 466

O’Brien CE., Com G., Fowlkes J., Tang XY., James LP. 
Peripheral quantitative computed tomography detects differences at the radius in prepubertal children with cystic fibrosis compared to healthy controls 
*PLoS One* 2018; 13: e0191013
Longitudinal Assessment of Children with Mild Cystic Fibrosis Using Hyperpolarized Gas Lung Magnetic Resonance Imaging and Lung Clearance Index  
American Journal of Respiratory and Critical Care Medicine 2018; 197: 397 - 400

Stahl M., Wielputz MO., Kauczor HU., Mall MA.  
The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis  
American Journal of Respiratory and Critical Care Medicine 2018; 197: 410 - 411

Verbanck S., Vanderhelst E.  
The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis  
American Journal of Respiratory and Critical Care Medicine 2018; 197: 409

Screening

Gini A., Zauber AG., Cenin DR., Omidvari AH., Hempstead SE., Fink AK., Lowenfels AB., Landsorp-Vogelaar I.  
Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer  
Gastroenterology 2018; 154: 556

Greaves RF., Jolly L., Massie J., Scott S., Wiley VC., Metz MP., Mackay RJ.  
Laboratory performance of sweat conductivity for the screening of cystic fibrosis  
Clinical Chemistry and Laboratory Medicine 2018; 56: 559 - 564

Hadjiliadis D., Khoruts A., Zauber AG., Mansionne P., Lowenfels AB.  
Pulmonary ventilation imaging in asthma and cystic fibrosis using oxygen-enhanced 3D radial ultrashort echo time MRI  
Journal of Magnetic Resonance Imaging 2018; 47: 1287 - 1297

Therapy

Awad SM., Berlinski A.  
Crossover Evaluation of Compressors and Nebulizers Typically Used by Cystic Fibrosis Patients  
Respiratory Care 2018; 63: 294 - 300

Bergamini G., Tridello G., Calcuterra E., Ceri S., Tagliasacchi M., Bianchi F., Monti F., Masciadri A., Laudanna E., Peserico D., Sorio E., Esposito V., Leal T., Assael BM., Sorio C., Melotti P.  
Ratiometric sweat secretion optical test in cystic fibrosis, carriers and healthy subjects  
Journal of Cystic Fibrosis 2018; 17: 186 - 189

Carrion A., Borowitz DS., Freedman SD., Siracusa CM., Goralski JL., Hadjiliadis D., Srinivasan S., Stokes DC.  
Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series  
Journal of Pediatric Gastroenterology and Nutrition 2018; 66: 451 - 454

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/CFTF or F508del/G551D-CFTF  
American Journal of Respiratory and Critical Care Medicine 2018; 197: 214 - 224

Flume PA., Wainwright CE., Tullis DE., Rodriguez S., Niknian M., Higgins M., Davies JC., Wagner JS.  
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTF mutation treated with ivacaftor  
Journal of Cystic Fibrosis 2018; 17: 83 - 88

Guimbellot JS., Acosta EP., Rowe SM.  
Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer  
Pediatric Pulmonology 2018; 53: E6 - E8

Harman K., Dobra R., Davies JC.  
Disease-modifying drug therapy in cystic fibrosis  
Paediatric Respiratory Reviews 2018; 26: 7 - 9

Hoo ZH., Boote J., Wildman MJ., Campbell MJ., Gardner B.  
Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers  
Health Psychology and Behavioral Medicine 2017; 5: 299 - 316

Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting  
Journal of Cystic Fibrosis 2018; 17: 89 - 95

Hudock KM., Clancy JP.  
An update on new and emerging therapies for cystic fibrosis  

Kim J., Davies Z., Dunn C., Wine JJ., Milla C.  
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles  
Journal of Cystic Fibrosis 2018; 17: 179 - 185

Konstan MW., VanDevanter DR., Sawicki GS., Pasta DJ., Foreman AJ., Neiman EA., Morgan WJ.  
Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis  

Kopp BT., McCulloch S., Shrestha CL., Zhang SZ., Sarzynski L., Woodley FW., Hayes D.  
Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis  
Pediatric Pulmonology 2018; 53: 583 - 591

Kramer EL., Clancy JP.  
TGF beta as a therapeutic target in cystic fibrosis  
Expert Opinion On Therapeutic Targets 2018; 22: 177 - 189

Lucarelli M.  
Next generation genetic studies and personalized therapy: the successful model of Cystic Fibrosis  
Biochimica Clinica 2018; 42: 44 - 50

May TL., Gifford AH., Lahiri T., Black A., Trang J., Cornell AG., Gonzalez K., Morin S., Naper M., Duarte CW., Zuckerman JB.  
Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study  
Archivos de Bronconeumologia 2018; 54: 232 - 234

Cystic Fibrosis Colorectal Cancer Screening Consensus

Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting  
Journal of Cystic Fibrosis 2018; 17: 89 - 95

Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting  
Journal of Cystic Fibrosis 2018; 17: 89 - 95

Hudock KM., Clancy JP.  
An update on new and emerging therapies for cystic fibrosis  

Kim J., Davies Z., Dunn C., Wine JJ., Milla C.  
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles  
Journal of Cystic Fibrosis 2018; 17: 179 - 185

Konstan MW., VanDevanter DR., Sawicki GS., Pasta DJ., Foreman AJ., Neiman EA., Morgan WJ.  
Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis  

Kopp BT., McCulloch S., Shrestha CL., Zhang SZ., Sarzynski L., Woodley FW., Hayes D.  
Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis  
Pediatric Pulmonology 2018; 53: 583 - 591

Kramer EL., Clancy JP.  
TGF beta as a therapeutic target in cystic fibrosis  
Expert Opinion On Therapeutic Targets 2018; 22: 177 - 189

Lucarelli M.  
Next generation genetic studies and personalized therapy: the successful model of Cystic Fibrosis  
Biochimica Clinica 2018; 42: 44 - 50

May TL., Gifford AH., Lahiri T., Black A., Trang J., Cornell AG., Gonzalez K., Morin S., Naper M., Duarte CW., Zuckerman JB.  
Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study  
Archivos de Bronconeumologia 2018; 54: 232 - 234


Nevis NJ., Thornton J., Murray CS., Dwyer T. Inhaled mannitol for cystic fibrosis. Cochrane Database of Systematic Reviews 2018; : 2:CD008649


Porsio B., Craparo EF., Mauro N., Giannatoni G., Cavallaro G. Mucus and Cell-Penetrating Nanoparticles Embedded in Nano-microformulations for Pulmonary Delivery of Ivcacfor in Patients with Cystic Fibrosis. ACS Applied Materials Interfaces 2018; 10: 165 - 181


Transplantation


Choi KJ., Cheng TZ., Honeybrook AL., Gray AL., Snyder LD., Palmer SM., Hachem RA., Jiang DW. Correlation between sinus and lung cultures in lung transplant patients with cystic fibrosis. International Forum of Allergy & Rhinology 2018; 8: 389 - 393